Abstract: The present invention relates to novel 11?-HSD inhibitors as well as to the use of 11 ?-HSD inhibitors for the manufacture of pharmaceutical agents for the prevention and/or treatment of metabolic diseases, cancer, cell proliferation, glaucoma, diseases associated with abnormal growth hormone secretion as well as wound healing disorders.